Publications by authors named "Alejandra Y Lopez Espinoza"
Article Synopsis
- TIGIT is an inhibitory receptor that competes with CD226 on immune cells, and targeting it may improve anti-tumor immunity, especially in exhausted CD8+ T cells and regulatory T cells.
- Combining different types of anti-TIGIT antibodies (Fc-enabled and Fc-silent) with another treatment showed varied effects on tumors: Fc-enabled antibodies reduced regulatory T cell numbers, while Fc-silent antibodies did not deplete these cells but enhanced the activity of tumor-specific CD8+ T cells.
- The study highlights that Fc-silent anti-TIGIT antibodies can drive antitumor responses by activating exhausted T cells without affecting regulatory T cells, indicating their potential for cancer therapy.
